[Progression of foundational and clinical studies on use of arsenic trioxide in treatment of lymphoma--review].
Arsenic trioxide has been used to treat lymphoma experimentally since it was used to treat acute promyelocytic leukemia successfully. Massive works in this field have been done throughout the world. It was found that arsenic trioxide exerted an anti-lymphomatic effect via many pathways, and many substances could increase or reduce this effect. Arsenic trioxide can be used to treat relapsed and refractory lymphomas resistant to other chemotherapies with some therapeutic effects and limited side effects, which indicates that arsenic trioxide is a new potential drug for lymphoma. This article is an overview about these foundational and clinical studies.
Li
Ling-Hao
LH
Department of Hematology, The Second People Hospital of Yunnan Province, Kunming 650021, China.
Li
Hui-Min
HM
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D010087:Oxides / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide